Jefferies downgraded Deciphera to Hold from Buy with a price target of $25.60, down from $26, after Ono agreed to acquire Deciphera for $25.60 per share in cash. The firm expects the deal to close by Q3, since Ono’s broad cancer pipeline is synergistic and has no real overlap with Deciphera, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.